Literature DB >> 26133157

Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?

Antonio Frontera1, D G Wilson2, H Sekhon3, E R Duncan3, G Thomas3.   

Abstract

Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac conditions. Atrial fibrillation (AF) has been demonstrated to be the most frequent arrhythmia encountered in HCM patients. Research focusing on AF and embolic stroke in HCM patients has been sparse and the sample size of most studies is small. The prognostic significance of AF in HCM patients is still not well known. The aim of this article is to provide further understanding of the anti-coagulation requirement of HCM patients with AF.

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Embolic stroke; Hypertrophic cardiomyopathy

Mesh：

Substances：

Year:  2015        PMID： 26133157     DOI： 10.1007/s00392-015-0876-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


  12 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy.

Authors:  A M Kizilbash; S K Heinle; P A Grayburn
Journal:  Circulation       Date:  1998-02-10       Impact factor: 29.690

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

4.  Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.

Authors:  I Olivotto; F Cecchi; S A Casey; A Dolara; J H Traverse; B J Maron
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

5.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.

Authors:  P M Elliott; J Poloniecki; S Dickie; S Sharma; L Monserrat; A Varnava; N G Mahon; W J McKenna
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

6.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

7.  P-wave durations as a predictor for atrial fibrillation development in patients with hypertrophic cardiomyopathy.

Authors:  Ozcan Ozdemir; Mustasa Soylu; Ahmet Duran Demir; Serkan Topaloglu; Omer Alyan; Hasan Turhan; Asuman Bicer; Emine Kutuk
Journal:  Int J Cardiol       Date:  2004-04       Impact factor: 4.164

8.  Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy.

Authors:  Maria-Angela Losi; Sandro Betocchi; Mariano Aversa; Raffaella Lombardi; Marianna Miranda; Gianluigi D'Alessandro; Alessandra Cacace; Carlo-Gabriele Tocchetti; Giovanni Barbati; Massimo Chiariello
Journal:  Am J Cardiol       Date:  2004-10-01       Impact factor: 2.778

9.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Morten Lock Hansen; Peter Riis Hansen; Janne Schurmann Tolstrup; Jesper Lindhardsen; Christian Selmer; Ole Ahlehoff; Anne-Marie Schjerning Olsen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  BMJ       Date:  2011-01-31

10.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.

Authors:  Konstantinos C Siontis; Jeffrey B Geske; Kevin Ong; Rick A Nishimura; Steve R Ommen; Bernard J Gersh
Journal:  J Am Heart Assoc       Date:  2014-06-25       Impact factor: 5.501
View more
  4 in total

1.  Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome.

Authors:  Tobias Zeus; Ulrike Ketterer; Daniela Leuf; Lisa Dannenberg; Florian Bönner; Rabea Wagstaff; Michael Gliem; Sebastian Jander; Malte Kelm; Amin Polzin
Journal:  Clin Res Cardiol       Date:  2015-10-29       Impact factor: 5.460

Review 2.  Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.

Authors:  Farbod Sedaghat-Hamedani; Elham Kayvanpour; Oguz Firat Tugrul; Alan Lai; Ali Amr; Jan Haas; Tanja Proctor; Philipp Ehlermann; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2017-08-24       Impact factor: 5.460

3.  Impact of body mass index on left atrial dimension in HOCM patients.

Authors:  Yue Zhou; Miao Yu; Jingang Cui; Shengwen Liu; Jiansong Yuan; Shubin Qiao
Journal:  Open Med (Wars)       Date:  2021-01-27

4.  Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.

Authors:  Jung-Chi Hsu; Ya-Ting Huang; Lian-Yu Lin
Journal:  Aging (Albany NY)       Date:  2020-11-23       Impact factor: 5.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.